Drug recall · September 2, 2026
Tyenne (tocilizumab-aazg) Injection recall
Why: Presence of particulate matter:An internal investigation at the firm found the product to contain glass particles.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, Illinois, 60047, NDC 65219-594-20.
- Lots / codes
Lot: 16UI07, Exp 08/31/2028
- Quantity
- 4,643 20mL-vials
- Company
- Fresenius Kabi USA, LLC, Lake Zurich, IL
- Distribution
- Nationwide in the USA
- Initiated
- August 10, 2026 · Voluntary: Firm initiated
- Classified
- September 1, 2026
- Reported
- September 2, 2026
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tyenne
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.